Ventyx Biosciences Announces Initiation of Dosing in a Phase 2a Trial of VTX3232 in Patients with Early Parkinson’s Disease
September 06, 2024 08:00 ET
|
Ventyx Biosciences, Inc.
SAN DIEGO, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a...
Ventyx Biosciences Announces Departure of Chief Financial Officer
August 30, 2024 08:00 ET
|
Ventyx Biosciences, Inc.
SAN DIEGO, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a...
Ventyx Biosciences to Participate in Two Upcoming Investor Conferences
August 28, 2024 08:00 ET
|
Ventyx Biosciences, Inc.
SAN DIEGO, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that...
Ventyx Biosciences Reports Second Quarter 2024 Financial Results and Highlights Recent Corporate Progress
August 08, 2024 16:01 ET
|
Ventyx Biosciences, Inc.
A Phase 2 obesity and cardiometabolic trial of VTX3232 and a Phase 2a trial of VTX3232 in patients with Parkinson’s disease are both expected to initiate in H2 2024 A Phase 2 trial of VTX2735 in...
Ventyx Biosciences Announces Results from the Phase 2 Trial of VTX958 in Participants with Moderately to Severely Active Crohn’s Disease
July 29, 2024 08:00 ET
|
Ventyx Biosciences, Inc.
The Phase 2 trial of VTX958 in Crohn’s disease did not meet its primary endpoint of change from baseline in mean CDAI score in either VTX958 dose group Both VTX958 dose groups achieved nominal...
Ventyx Biosciences Announces Positive Preclinical Data for CNS-Penetrant NLRP3 Inhibitor VTX3232 Demonstrating Reversal of Obesity and Improvements in Cardiometabolic and Inflammatory Markers
June 05, 2024 16:01 ET
|
Ventyx Biosciences, Inc.
VTX3232 demonstrated improvements in body weight, systemic inflammatory biomarkers and cardiometabolic parameters in diet-induced obesity (DIO) mice Additive effects were observed for VTX3232 in...
Ventyx Biosciences to Participate in Three Upcoming Investor Conferences
May 16, 2024 16:05 ET
|
Ventyx Biosciences, Inc.
SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a...
Ventyx Biosciences Announces Appointment of Matthew Moore as Chief Operating Officer
May 16, 2024 08:00 ET
|
Ventyx Biosciences, Inc.
SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a...
Ventyx Biosciences Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Progress
May 09, 2024 16:01 ET
|
Ventyx Biosciences, Inc.
Phase 2a trials of CNS-Penetrant NLRP3 Inhibitor VTX3232 to initiate in H2 2024 in patients with early Parkinson’s disease and in participants with obesity with certain additional cardiovascular risk...
Ventyx Biosciences to Report First Quarter 2024 Financial Results on May 9, 2024
May 02, 2024 16:05 ET
|
Ventyx Biosciences, Inc.
SAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a...